Pretreated patients with advanced pancreatic cancer. MedDRA version: 21.1 Level: LLT Classification code 10033605 Term: Pancreatic cancer metastatic System Organ Class: 100000004864 MedDRA version: 21.0 Level: LLT Classification code 10033606 Term: Pancreatic cancer non-resectable System Organ Class: 100000004864 MedDRA version: 21.0 Level: LLT Classification code 10033607 Term: Pancreatic cancer recurrent System Organ Class: 100000004864
Conditions
Sponsors
Department of Oncology, Herlev & Gentofte Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Signed informed consent: - Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care - Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study • Histological or cytological confirmation of locally advanced or metastatic pancreatic carcinoma prior to entering this study • Prior therapy requirements: o For Part A : there is no upper limit on the number of prior chemotherapy regimens received. Patients must have received and progressed during or after at least 1 line of systemic chemotherapy in the metastatic setting (gemcitabine or 5-FU based regimens). o Notes: - If a participant received adjuvant/neoadjuvant systemic combinational therapy, and progressed within 6 months, the adjuvant/neoadjuvant treatment will be considered as 1 line of systemic treatment. - In general, discontinuation of 1 drug in a multi-drug regimen and continuation of other drug(s), is considered part of the same line of treatment. Restarting the same regimen after a drug holiday or maintenance chemotherapy can also be considered part of the same line of treatment. Switching from IV (5-FU) to an oral formulation (capecitabine) of the same drug is also considered part of the same line of treatment -Minimum time from first systemic therapy for recurrent/metastatic adenocarcinoma of pancreas to progression should be at least 3 months • Age 18 years and older • ECOG/WHO Performance Status (PS) 0-1 • All participants will be required to undergo mandatory pre- and on-treatment biopsies at acceptable clinical risk as judged by the investigator. An archival pre-treatment sample is not acceptable. • Patients must have normal organ and marrow function as defined below: - Absolute neutrophil count (ANC) = 1.5 x 10?/L - Platelet count = 100 x 10?/L - Serum bilirubin = 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin = 50 mmol/L) - AST/ALT = 5 x ULN - Serum creatinine = 1.5 x ULN or CrCl = 40 mL/min (using the Cockcroft-Gault formula) • Women of childbearing potential (WOCBP) must use method(s) of contraception as indicated in Appendix 3. For a teratogenic study drug and/or when there is insufficient information to assess teratogenicity (preclinical studies have not been done), a highly effective method(s) of contraception (failure rate of less than 1% per year) is required. The individual methods of contraception and duration should be determined in consultation with the investigator. WOCBP must follow instructions for birth control when the half-life of the investigational drug is greater than 24 hours, contraception should be continued for a period of 30 days plus the time required for the investigational drug to undergo five half-lives. The half-life of nivolumab and ipilimumab is up to 25 days and 18 days, respectively. WOCBP should therefore use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. The investigator shall review contraception methods and the time period that contra
Exclusion criteria
Exclusion criteria: • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results • Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll • Current or prior use of immunosuppressive medication within 14 days before the first dose of ipilimumab, nivolumab and tocilizumab. The following are exceptions to this criterion: - Intranasal, inhaled, or topical steroids; or local steroid injections (e.g. intra-articular injection) - Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent - Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication) • Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) • Allergies and Adverse Drug Reaction: - History of allergy to study drug components - History of severe hypersensitivity reaction to any monoclonal antibody • WOCBP who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: For PART A LEAD IN : To assess the efficacy of ipilimumab, nivolumab and tocilizumab in combination with SBRT in terms of objective response rate (ORR). ;Secondary Objective: For PART A : To assess the efficacy of the ipilimumab, nivolumab and tocilizumab in combination with SBRT in terms of DoR, DCR, PFS, PFS2, PFS4, PFS6, OS, OS6, and OS12 To assess the health-related QoL in metastatic PC patients treated with ipilimumab, nivolumab and tocilizumab in combination with SBRT as measured by EORTC QLQ-C30 global QoL scale To assess the safety and tolerability profile of ipilimumab, nivolumab and tocilizumab in combination with SBRT ;Primary end point(s): For PART A : ORR in all patients using Investigator assessments according to RECIST 1.1 ;Timepoint(s) of evaluation of this end point: For PART A Interim analyse for desicion to proceed to part B - at the time the last of the planned 30 patients has completed 2 post-baseline tumor assessments (at Weeks 8 and after week 16 +/- 1week) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): For PART A : DoR, DCR, PFS, PFS2, PFS4 and PFS6 in all patients using Investigator assessments according to RECIST 1.1 OS, OS6, and OS12. Adjusted mean change from baseline in global QoL score from the EORTC QLQ-C30 questionnaire. AEs, physical examinations, laboratory findings (including clinical chemistry, hematology), vital signs (including blood pressure and pulse). ;Timepoint(s) of evaluation of this end point: Final analysis 1 year after inclusion of last patient | — |
Countries
Denmark
Contacts
Public ContactPI Inna Chen
Department of Oncology, Herlev & Gentofte Hospital
Outcome results
None listed